Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, November 17, 2010 - Anascorp


Submission Type: BLA    Submission ID: 125335/0    Office: OBRR
Product: Centruroides (Scorpion) Immune F(ab)2 Intravenous (Equine)
Applicant:Instituto Bioclon, S.A. de C.V.
Telecon Date/Time: 17-Nov-2010 11:00 AM        Initiated by FDA? Yes
Telephone Number:
Communication Categorie(s):
1. Advice
Telecon Summary:Discussion of Applicant Change
FDA Participants: Debbie Cordaro
Non-FDA Participants: -------(b)(4)----------
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:

The applicant indicated that a business decision was being discussed to transfer ownership of this product from Instituto Bioclon, S.A. de C.V. to Rare Disease Therapeutics, Inc. (RDT). If the transfer occurs, Instituto should submit a correspondence to this file explaining the transfer and include information how, if at all, the manufacture of the product will be affected. A revised Form FDA 356h, with the new applicant information, must be submitted. The applicant will also need to submit revised labeling that indicates RDT is the applicant.

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English